| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Human RCTs exist for collagen peptide blends including Type III, primarily in skin and wound healing. Type III-specific isolation in trials is less common — most trials use mixed collagen hydrolysates. |
20 / 25 |
| Sample Size | Studies using collagen blends containing Type III typically enroll 50-150 participants. Moderate sample size. |
16 / 20 |
| Replication | Collagen peptide blend research well replicated; Type III-specific isolation less so. Replicated within the broader collagen peptide evidence base. |
15 / 20 |
| Journal Impact Factor | Same publication venues as Type I — Skin Pharmacology and Physiology, Nutrients, Dermatology journals. IF 3-4 range. |
8 / 15 |
| Funding Independence | Similar to Type I — collagen industry (GELITA, Rousselot) funds meaningful portion. Pre-registered but industry-dominant. |
4 / 10 |
| Population Diversity | Studied across skin and wound healing populations — reasonably diverse age and sex distribution. |
3 / 5 |
| Researcher h-Index | Overlapping researcher pool with Type I collagen. Oesser and collagen peptide researchers consistently. |
2 / 5 |